The global tissue banking market size was valued at USD 11,617.43 million in 2022. It is projected to reach USD 21,667.40 million by 2031, growing at a CAGR of 5.83% during the forecast period (2023-2031).
The procedure of gathering, processing, and conserving transplantable human tissues for possible therapeutic purposes is referred to as tissue banking. The tissues recovered are used to repair and replace the patients' damaged or missing tissues. Injuries to the spinal cord, damaged heart muscles, and skin from severe burns can all be treated with them. Developments in biomedical research and clinical trials drive the need for tissue banking and preservation. These tissues are utilized to restore limb function, lessen pain, and enhance the quality of life for patients. Additionally, the industry is driven by the new trend of cosmetic surgery due to rising disposable income and body consciousness among people.
The primary reason projected to propel the growth of the global market globally is the rising healthcare costs directly proportional to the rising number of people with chronic conditions. The National Health Expenditure Projections 2018-2027 study from the Centers for Medicare and Medicaid Services (CMS) projects that national health spending in the United States will increase at an average rate of 5.5% each year for 2018–2027 and will reach about USD 6.0 trillion by that year. The growing senior population raises the cost of healthcare. The rise in service expenses, particularly for inpatient hospital care for chronic illnesses, is to blame for the increase in healthcare spending. Moreover, since most of the costs are paid by public and private insurance, healthcare costs have recently increased.
Additionally, it is anticipated that over time, the cost of healthcare will rise due to the rising need for transplantation and regenerative medicine and the growing reliance of the global population on modern medical technologies. The global market is expected to expand significantly throughout the projected period in light of the causes above.
By enabling patient specimens to be stored in settings conducive to evaluating biomarkers that forecast treatment results, tissue banks open the path for implementing customized, personalized medicines in clinical practice. With the increasing availability of transplantable cadaver tissue and the growing number of clinical indications, particularly in orthopedic, plastic, and cardiovascular surgery, as well as in the treatment of cancer, tissue banking refers to the collection and recovery of human tissues for allograft transplantations in a clinical setting. When adult cancer patients need rapid treatment or do not want to undergo ovarian stimulation, ovarian tissue cryopreservation and transplantation are effective alternatives for preserving fertility. Additionally, the only alternative for preserving the fertility of prepubescent cancer patients is ovarian tissue freezing. Therefore, a key factor influencing the market under study is the increased prevalence of malignancies.
Human tissue collection and banking have become more prevalent in recent years. The study market is anticipated to face challenges due to the ethical issues and strict requirements that tissue banking raises. Different national laws govern the acquisition of human tissue, with restrictions based on things like whether the donor was alive or dead at the time of donation, the purpose of the tissue removal (therapeutic or additional to therapeutic and diagnostic requirements), the donor's mental capacity at the time of tissue removal, and whether or not medical records will be needed and, if so, whether or not they will be anonymized.
Various regulatory agencies were set up to address these concerns about tissue banking globally. All of the laws and rules have as their ultimate objective the implementation of openness, evidence-based standards, consistency in the quality of human grafts and services, and operation within an ethical framework, all of which are essential for preserving the public's confidence in public healthcare systems. The tissue banking market is expected to experience restraint over the forecast period due to the aforementioned strict regulations implemented by almost all countries in the world regarding tissue banking and the prohibition on commercializing human tissues for various purposes.
One of the key factors anticipated to support the studied market throughout the forecast period is the growing investment and technological improvements made by most pharmaceutical organizations in drug discovery and development operations. To better understand diseases' molecular diversity and find new targets for therapeutic interventions, tissue banking offers a research infrastructure that supports the discovery and development of new drugs. Basic research into disease pathophysiology, target validation, hit-to-lead identification, safety and efficacy assessment, biomarker discovery, and companion diagnostic development can all benefit from the use of human tissues. Target validation, which involves determining if a prospective drug target is present throughout a disease or only at specific stages, is the most crucial step in drug discovery. As a result, human tissues are essential in controlling the activity of specific pharmacological targets that will have therapeutic advantages. Isolated tissues can study complicated organ and system responses to medication.
| Study Period | 2019-2031 | CAGR | 5.83% |
| Historical Period | 2019-2021 | Forecast Period | 2023-2031 |
| Base Year | 2022 | Base Year Market Size | USD 11,617.43 Million |
| Forecast Year | 2031 | Forecast Year Market Size | USD 21667.40 Million |
| Largest Market | North America | Fastest Growing Market | Europe |
The global tissue banking market is divided into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant revenue contributor and is expected to grow at a CAGR of 5.67% during the forecast period. There is an increase in chronic illnesses and disorders. It led to heart disease, which burdens individuals, communities, healthcare providers, and systems. Cardiovascular disease affects almost half of all individuals in the United States. In 2020, the GLOBOCAN predicted that there would be 6,12,390 cancer-related fatalities in the United States and 22,81,658 newly diagnosed cases of the disease. Breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, and skin cancer are the most prevalent malignancies in the US. The number of diabetes cases is predicted to rise, as a result of which the number of potential donors for tissue banks is growing as the prevalence of chronic diseases increases. This is anticipated to accelerate market expansion in the U.S. With 120 accredited tissue banks and almost 1,800 individual members, the American Association of Tissue Banks is the only tissue bank association in the nation. These banks collect tissues from more than 39,000 donors and offer them to doctors, students, and research organizations to further medical education and create more effective treatments for illness, injury, and disease. The healthcare system in Canada is better and offers higher-quality services. The demand for tissue banks in the nation will be fueled by elements including the increased prevalence of chronic diseases across all age groups, particularly the aging population.
Europe is expected to grow at a CAGR of 5.80% during the forecast period. The market under study is expanding quickly because the United Kingdom has a robust healthcare system and a developing healthcare sector. The market is becoming more lucrative as chronic diseases, including diabetes, cardiovascular disease, and others, are becoming more common. In the U.K., in 2019, 4.8 million people had diabetes diagnoses, according to "The British Diabetic Association." This suggests that the increasing desire for a cure or effective illness management is driving up the price of numerous treatments, encouraging the expansion of the market under investigation. The U.K. currently has 1,195 clinical trials registered, according to data from clinicaltrials.gov. Therefore, it is anticipated that the demand for tissue samples will increase over the projected period due to the country's growing number of clinical trials.
Well-established tissue banks are also present in the nation, which is anticipated to favorably impact the industry under investigation. For instance, one of the UK's largest and most distinctive tissue collections is that of the Children's Cancer and Leukaemia Group Tissue Bank. The German Society for Tissue Transplantation (DGFG) coordinates tissue donation campaigns nationwide and offers patients bone grafts, amniotic tissue, heart valves, and corneal transplants. DGFG, between 2013 and 2018, donated approximately 20,071 corneas, 748 heart valves, and 721 blood vessels. DGFG continues to provide patients with safe tissue transplants despite the epidemic. Therefore, these variables likely spur the German market under study to rise. The burden of chronic diseases, the expanding number of clinical trials, the government's emphasis on clinical research, and technical advancements in drug discovery and development are just a few of the key drivers influencing the tissue banking industry.
In China, one of the essential factors driving the market expansion is the increase in research and development activities by pharmaceutical and biopharmaceutical businesses. The first regional tissue bank in China, Shanxi Provincial Tissue Bank, SPTB, which offers tissue allograft, is supported by the International Atomic Energy Agency (IAEA) in terms of tissue banking. Therefore, the dominant growth factor for the market under study is the increasing emphasis on clinical research, regenerative medicines, technological advancements, and the rising number of chronic illnesses. Particularly in the biotechnology sector, South Korea is progressively emerging as one of the major players in the pharmaceutical industry. The South Korean government claims that this country is responsible for 4% of all pipeline research worldwide. In South Korea, around 11,524 clinical studies are being conducted, according to information supplied by clinicaltrials.gov (2020).
The Gulf Cooperation Council (GCC) region comprises Saudi Arabia, Kuwait, Bahrain, Qatar, the United Arab Emirates, and Oman. Rising chronic diseases and increased research and development efforts fuel the overall market growth in GCC nations. With intentions to carry out at least 20 stem cell transplantations per year, it was anticipated that the National Centre for Cancer Care and Research (NCCCR) would concentrate on creating a stem cell donor registry in Qatar. The market for tissue banking in South Africa is expanding due to expanding R&D, rising chronic disease rates, and increased demand for cutting-edge pharmacological therapies. Despite being a developing country, South Africa's biopharmaceutical and healthcare sectors are still in their early stages of development. But initiatives are being made to encourage innovation in pharmaceutical and biopharmaceutical research.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Based on product, the global market is bifurcated into equipment and media and consumables.
The media and consumables segment is the highest contributor to the market and is estimated to grow at a CAGR of 5.70% during the forecast period. By blocking all metabolic activity, the cryopreservation process allows for a continual supply of living cells that are genetically stable and can be used for treatments like bone marrow transplants and organ donations, among others. As a result, different types of cryopreservation equipment are needed for this operation. Cryopreservation equipment is the name given to the machinery used to preserve biological material. Sperms, plant seeds, embryos, and eggs, as well as other biological resources useful for future research, are frequently preserved.
Furthermore, the market analyzed during the forecast period has also been boosted by increased clinical and research investigations using cryopreservation equipment in stem cell applications. The idea of collecting and storing stem cells for later use was first proposed with the development of contemporary cryopreservation technologies. To minimize contamination, incorrect labeling, and tissue degeneration, tissue banks need specialized processing and storage facilities. Temperature, humidity, and air quality are crucial tissue bank factors that must be monitored regularly. Considering the uniformity and cleanliness of the tissue, the Continuous Monitoring System helps to guarantee ongoing management of the conditions and ensure that the conditions connected to the treatment and storage of the tissue transplants are adequate.
Different forms of biopreservation media are available and can also be either solid or liquid. For instance, nutrient media includes minerals as enzyme activators and osmotic pressure maintainers, peptones as a source of nitrogen, carbohydrates as a carbon source, and additional supplements like vitamins, amino acids, and others. Agar-agar, agarose, gelatins, and other solidifying agents can create solid media. It also has a buffer mechanism to keep the pH range within ideal limits. Either homemade or commercially produced premade media are acceptable. The use of media and consumables in tissue banking is widespread. Several containers are required, depending on the kind and amount of items that will be preserved. For instance: Cryomolds and cryovials can both be used to store tissues. Additionally, as technology advances, there will be a greater need for media and consumables, which will fuel the expansion of the market under study.
Based on application, the global market is bifurcated into therapeutics, medical research, and other applications.
The therapeutics segment owns the highest market and is estimated to grow at a CAGR of 5.96% during the forecast period. Tissue banks are organizations with the physical facilities, technological tools, and staff required to identify, transport, process, pack, store, and distribute human tissue for medical purposes. Tissue banks are the most crucial source of information for research. Still, they also play a vital part in offering a range of regenerative medicine and tissue engineering treatment options for difficult-to-treat disorders such as chronic heart failure, stroke, and osteoarthritis. Novel technologies that hold considerable potential for future medicinal benefits are advances in tissue banking. New therapeutic uses for human tissue and stem cells in treating uncommon diseases, regenerative medicines, and tailored therapies are anticipated to expand the market. The main drivers of the therapeutics industry growth are the commercial agreements between diverse companies for customized medicine applications.
Research using human tissue is becoming increasingly important in understanding human disease. A tissue bank is a crucial tool for any research and development project since it makes it possible to examine the effects of various chronic diseases, including cancer. These prevalent and expensive long-term health issues have steadily risen due to societal changes and an aging population. Additionally, it is anticipated that the growing trend of creating disease-specific banks will hasten the expansion of tissue banking. As they gather pathological tissue samples and related data from donors afflicted with a particular condition, these significantly impact research studies, including the discovery of biomarkers, drug development, and, generally, research on treating diseases or tumors. Additionally, the steps done by the government and other organizations to promote and support tissue banks will also aid in the expansion of the business.
